The first drug for skin cancer markets, Britain
Became the first new treatment for advanced skin cancer is available for sale in the British market for the first time since the seventies of the last century.
The Daily Telegraph said that half of the patients who took the new drug in the trials were still alive after a year, and accounted for poor who were not given the drug.
It is noteworthy that the drug named Aapelemopab injected four times, and works in a teaching body's immune system to resist disease, also known as melanoma.
The newspaper reported that the new drug license granted approval by the European Medical Agency, but the question of its effectiveness and its price is still under evaluation by the British health rationing "Nice" and then it is not available widely in the British medical services.
And patients can progress to cancer drugs fund the government's to get the drug marketed by Bristol-Myers Squibb under the name Aarvoje, which cost about 123 thousand dollars to four intravenous injections.
The officials said one area that the license for the drug represents a real advance in the treatment of patients with advanced skin cancer treatment since it is the first thirty years in Britain prolong the life expectancy of the patient, which is a significant leap forward.
It is known that skin cancer affects dramatically in adolescents and young adults and the rates increase rapidly in Britain. Are diagnosed each year 11,700 people the most dangerous types of cancers, malignant melanoma, and died about two thousand in a few months after the spread of the tumor throughout the body in the advanced stage.
The only treatment that was available since the seventies was a sort of an old name dacarbazine chemotherapy.
According to recent clinical trials that Aapelemomab more effective in the treatment of melanoma and its side effects was also lower. Patients receive four injections at a rate of one every three weeks.
During the latter part of the experiment on patients who have undergone prior treatment for skin cancer, 46% of those who took the new drug were still alive after one year compared with 25% who had not given the drug.
Furthermore, 24% was still alive after two years compared to 14% of those who did not take the drug and the average survival 10.1 months compared with 6.4 months among those who were not given the drug.
